These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

823 related items for PubMed ID: 18681215

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Obstacles and progress toward development of a preventive HIV vaccine.
    Heyward WL, MacQueen KM, Jaffe HW.
    J Int Assoc Physicians AIDS Care; 1997 Aug; 3(8):28-34. PubMed ID: 11364630
    [Abstract] [Full Text] [Related]

  • 24. HIV-1 and AIDS: what are protective immune responses?
    Beattie T, Rowland-Jones S, Kaul R.
    J HIV Ther; 2002 May; 7(2):35-9. PubMed ID: 12553686
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Why vaccines are not the answer - the failure of V520 and the importance of cell-mediated immunity in the fight against HIV.
    White A.
    Med Hypotheses; 2008 Dec; 71(6):909-13. PubMed ID: 18768264
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. The hunt for the AIDS vaccine.
    Essex M.
    AIDS Asia; 1995 Dec; 2(3):10-3. PubMed ID: 12319586
    [Abstract] [Full Text] [Related]

  • 32. [AIDS vaccines: an enigma in vaccine development].
    Dorner F, Barrett N.
    Wien Klin Wochenschr; 1990 Jan 19; 102(2):51-8. PubMed ID: 1689919
    [Abstract] [Full Text] [Related]

  • 33. The adjuvancy of OX40 ligand (CD252) on an HIV-1 canarypox vaccine.
    Liu J, Ngai N, Stone GW, Yue FY, Ostrowski MA.
    Vaccine; 2009 Aug 13; 27(37):5077-84. PubMed ID: 19573639
    [Abstract] [Full Text] [Related]

  • 34. Current approaches to developing a preventative HIV vaccine.
    Tonini T, Barnett S, Donnelly J, Rappuoli R.
    Curr Opin Investig Drugs; 2005 Feb 13; 6(2):155-62. PubMed ID: 15751738
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Executive summary and recommendations from the WHO/UNAIDS/IAVI expert group consultation on 'Phase IIB-TOC trials as a novel strategy for evaluation of preventive HIV vaccines', 31 January-2 February 2006, IAVI, New York, USA.
    WHO/UNAIDS/IAVI International Expert Group.
    AIDS; 2007 Feb 19; 21(4):539-46. PubMed ID: 17301582
    [Abstract] [Full Text] [Related]

  • 37. Policy rebuttal. HIV vaccine trial justified.
    McNeil JG, Johnston MI, Birx DL, Tramont EC.
    Science; 2004 Feb 13; 303(5660):961. PubMed ID: 14963313
    [No Abstract] [Full Text] [Related]

  • 38. Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: a review.
    Girard MP, Osmanov S, Assossou OM, Kieny MP.
    Vaccine; 2011 Aug 26; 29(37):6191-218. PubMed ID: 21718747
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 42.